Methods: A novel series of isoxazole (S21-S30) derivatives were designed, synthesized and screened
for their anticancer activity against estrogen receptor-positive MCF-7 and negative MDA-MB-435 breast cancer
cell lines. The synthesized derivative has the ability to inhibit the growth of the human breast cancer cell line at
low concentrations. In vivo anticancer activity was performed on virgin female sprague dawley rats.
Results: The result shows that compound S23 has more selectivity and marked estrogen modulator activity than
the standard tamoxifen.
Keywords: Chalcone, isoxazole, breast cancer, estrogen receptor, S21-S30, tamoxifen.
Rights & PermissionsPrintExport